<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01726959</url>
  </required_header>
  <id_info>
    <org_study_id>MRS1</org_study_id>
    <nct_id>NCT01726959</nct_id>
  </id_info>
  <brief_title>Prediction of Methotrexate Response - A Pilot Study</brief_title>
  <acronym>MRS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrium Health</source>
  <brief_summary>
    <textblock>
      The objective of this study is to identify genetic predictors of individual methotrexate&#xD;
      (MTX) response in patients with rheumatic diseases by determining genetic and metabolomic&#xD;
      factors related to nutrient metabolism and drug transport.&#xD;
&#xD;
      The development of better genetic predictors of individual MTX treatment response would&#xD;
      provide invaluable prognostic information prior to initiating treatment, which would allow&#xD;
      more appropriate choice of therapy, decreased adverse events, and more efficient&#xD;
      dose-escalation of the drug, with ultimate benefits of improved effectiveness and&#xD;
      tolerability rates in patients being treated with MTX for autoimmune diseases.&#xD;
&#xD;
      Despite being the gold-standard therapy for rheumatoid arthritis and other types of chronic&#xD;
      autoimmune diseases since 1951, MTX's efficacy and safety profile limit its use: MTX is&#xD;
      discontinued in greater than 50% of patients secondary to inefficacy or poor tolerability.&#xD;
      Upon initial treatment, discontinuation rates approach 12% because of drug toxicity, despite&#xD;
      prophylactic measures such as the co-administration of folic acid. The causes of primary&#xD;
      failure, secondary failure, and adverse events of MTX may be related to genetic variation of&#xD;
      dihydrofolate reductase (DHFR) and other genes involved in folate metabolism, one-carbon&#xD;
      transfer, and drug transport. The purpose of this study is to identify genetic variations&#xD;
      involved in methotrexate response so that we may better understand the pharmacodynamics of&#xD;
      MTX metabolism in patients with rheumatic diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Rheumatic Diseases</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <description>Methotrexate for rheumatic diseases, 2.5 - 25 mg weekly</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with rheumatic disease being newly treated with methotrexate, recruited from a&#xD;
        single rheumatology practice&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult patients (i.e. &gt;18 years of age) who are enrolled at NorthEast Rheumatology&#xD;
             at the Carolinas Medical Center - NorthEast who will be initiating MTX as standard&#xD;
             treatment for their particular rheumatic disease, which may include (but not be&#xD;
             limited to) conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing&#xD;
             spondylitis, inflammatory-bowel disease related arthropathies, lupus (systemic lupus&#xD;
             erythematosus, cutaneous lupus erythematosus), Sjogren's syndrome, Behcet's disease,&#xD;
             systemic sclerosis, and vasculitides.&#xD;
&#xD;
          -  No prior enrollment into this study&#xD;
&#xD;
          -  Enrollment and initial blood sample collection prior to first MTX administration&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NONE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon K. Lam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolinas Medical Center - NorthEast Rheumatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheri Brosnahan, RN, OCN, CCRC</last_name>
    <phone>704-403-4165</phone>
    <email>sheri.brosnahan@carolinashealthcare.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carolinas Medical Center - NorthEast</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Brosnahan, RN, OCN, CCRC</last_name>
      <phone>704-403-4165</phone>
      <email>sheri.brosnahan@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Gordon K Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 12, 2012</study_first_submitted>
  <study_first_submitted_qc>November 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2012</study_first_posted>
  <last_update_submitted>February 5, 2013</last_update_submitted>
  <last_update_submitted_qc>February 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Gordon Lam</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

